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In its brief history, Rosetta
Inpharmatics, Inc. (Kirkland, WA) has
generated a lot of data. Data from
25 000 whole genome array scans, for
starters. The company believes that
the sheer volume of its data bank is
the key to its future success.
When analyzing DNA expression
arrays, Rosetta claims that more is
more because more allows you to
detect patterns of co-regulated genes.
‘‘People have assumed that the root
information is at the single transcript
level,’’ says Rosetta CEO Stephen
Friend, ‘‘but we are looking for
patterns.’’ Once Rosetta has
accumulated enough patterns arising
from known perturbations, says
Friend, the company will be able to
deconvolute the changes arising from
any uncharacterized state, such as a
disease or drug treatment. From there
it is a short journey to the
identi¢cation of drug targets, and the
assessment of whether a drug will
cause unwanted side-effects.
From the clinic to the boardroom
Friend’s foray into company land was
prompted by his clinical training. ‘‘As
a pediatric oncologist I was getting
more frustrated at how few of the
targets and exciting biology ever got
into therapeutic applications,’’ he
says. He took a sabbatical year to look
at where the inef¢ciencies were in the
drug pipeline. ‘‘It was really an eye-
opener,’’ he says. ‘‘It became really
clear the role that serendipity ^ or
brute force ^ played.’’
He ¢rst attempted to reduce the
serendipity factor by using a more
intelligent approach. With Lee
Hartwell and the Fred Hutchinson
Cancer Research Center he set up the
Seattle Project. The idea was to use
model organisms ^ notably budding
yeast ^ that were defective in a
pathway that is also defective in
cancer cells, and then screen for
chemicals that selectively kill these
strains. This idea ^ dubbed
‘‘compounds that kill in a context’’ by
Friend ^ was ‘‘an idea that could’ve
become a company,’’ he says. For now
it remains in the public sector. Tens of
thousands of compounds have been
analyzed in a collaboration with the
National Cancer Institute.
Rosetta has found the key to
interpreting mountains of data.
Generate more of it
Just as Friend was getting the
Seattle Project started, DNA
microarrays made their big entry. By
1995 chips were being made by both
the cDNA spotting method of Patrick
Brown (Stanford University, Stanford,
CA; later exploited by Synteni, Inc.
before it was bought by Incyte
Genomics, Inc. (Palo Alto, CA)) and
the photolithographic synthesis of
oligonucleotides developed by
Affymetrix, Inc. (Santa Clara, CA).
With the encouragement of genomics
guru Leroy Hood (University of
Washington, Seattle, WA), Friend
considered a new kind of brute-force
approach to drug discovery based on
DNA chips.
‘‘We were thinking about how
you might use the genome as a
sensor,’’ he says. With further study
Friend realized that ‘‘the ripple-down
effects when you disrupt one protein
are really tremendous [because] the
cell is hard-wired together.’’ Arrays
could be used to detect those ripple
effects.
Array companies already existed.
But still Friend felt there was a gap in
the market. ‘‘The companies that
were out there were interested in
arrays as an end,’’ he says. ‘‘There
were companies that could make
arrays but there weren’t people
working out how to use them to
impact drug discovery. It was more
‘isn’t this a great technology’.’’ In
contrast, he says, ‘‘we could see that
there would be a large mass of data
coming off the arrays and no one
would know how to use it.’’
Jet-powered arrays
One of Rosetta’s early assets was a
new method of making arrays. Alan
Blanchard, ¢rst at Caltech (Pasadena,
CA) and then with Hood, had been
working on converting garden-variety
ink-jet computer printers into DNA
synthesizers. The simplest version of
the machine simply spits
oligonucleotides onto a glass surface,
as does a bubble-jet device recently
unveiled by the Canon Research
Center (Kanagawa, Japan). But
Blanchard’s device can also be used to
synthesize oligonucleotides of up to
70^80 nucleotides in situ.
Ink-jet arrays avoid the complexity
and expense of photolithography, and
offer greater control over spot size
(and thus greater precision and higher
density) than conventionally spotted
arrays. For the past year Rosetta has
been using 3 inch by 3 inch arrays that
cover the majority of transcripts from a
genome. But Rosetta was not looking
to become an array company, so they
have transferred rights to the ‘FlexJet’
technology to Agilent Technologies,
Inc. (Palo Alto, CA). Commercial
release of the FlexJet arrays by
Agilent is expected by the end of the
year 2000.
Software and databases
What Rosetta does sell is a database
with reference expression patterns,
and Rosetta Resolver1, a software
package to analyze existing and newly
generated array data.
Resolver stores data in a particular
architecture so that the data can be
called up and queried. It has some
proprietary algorithms and tools in
addition to the common public-
domain programs, and most
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importantly the different tools are
integrated.
Rosetta is releasing some parts of
the Resolver package for free. These
tools use a Gene Expression Markup
Language (GEML) to convert diverse
expression data into a standard format.
But the integrated storage and
analysis package is not cheap. Prices
range from $250 000 for a system
allowing two concurrent users, to
$1 million for larger systems.
The need for Resolver comes back
to the volume of data. ‘‘Very few
academics can afford to put a real
database back end on the
experiments,’’ says Mark Boguski,
Rosetta’s senior vice-president of
research and development. And yet,
he says, ‘‘you need coherent data sets
to make reliable predictions. That
requires the assimilation of large
amounts of data collected in a
controlled fashion. Only then do you
believe the data.’’ Rosetta generates
coherent data sets in customized
collaborations that are separate from
Resolver itself.
‘‘Having a limited number of data
sets, the academics focus on the low-
lying fruit,’’ says Boguski. Richard
Hynes of the Massachusetts Institute
of Technology (Cambridge, MA)
admits as much, based on his recent
array experiments in which he found a
role for RhoC in metastasis. ‘‘We
deliberately set our threshold quite
high to eliminate the noise,’’ he
says. ‘‘When we set it that high
there weren’t many genes left to deal
with.’’
But Rosetta reported in a recent
paper in Cell (vol. 102, p. 109) that
changes as low as 1.5-fold were often
the most important, and according to
Boguski ‘‘you need a tremendous
amount of data to see that level.’’
The Cell paper is a test case for the
Rosetta method. ‘‘We’re putting our
effort into how to design
experiments,’’ says Boguski. ‘‘Three
years ago if you had asked us what is
important it would have been
monitoring individual transcript
levels,’’ says Friend. Most researchers
still focus on this approach: what is up,
and what is down, for example, during
the cell cycle. But Rosetta realized
that there would never be enough
easily scored phenotypes to
characterize every gene.
The best way to cover all yeast
genes comprehensively was to score
the patterns of changes in a vast panel
of mutants. (With other organisms
Rosetta will have to fall back on
scoring a mixture of phenotypes, but
the idea of analyzing a vast collection
of changes (not just the change of
interest) remains.) In the Cell study,
patterns from 300 yeast mutants and
drug treatments were used to assign
eight uncharacterized genes to four
different pathways and determine one
drug target. The drug target was clear
based on the similarity of the
expression patterns after either drug
treatment or mutation of the gene
encoding the targeted protein.
Along the way has come a pleasant
surprise. ‘‘When we ¢rst thought
about doing this, we thought there
would be a ten to twenty year cycle of
[deciphering patterns] because people
would want to know the why ^ what
the pattern meant,’’ says Friend. But
‘‘the important thing was to say how
similar the patterns are. The pattern
recognition can go on without
understanding the why.’’
The long-term plan for Rosetta is to
partner with drug companies in
speci¢c areas of biology to provide
extensive gene expression services. A
major function of those services will
be to detect the likelihood of a drug
producing a side-effect. Whole-
genome arrays should enable Rosetta
to detect all the effects of a drug on a
cell, including those directed against
unanticipated targets that cause side-
effects. Drugs could be re-designed to
avoid such interactions before the
drugs enter the clinic. Competition
may come from a planned company
called Merrimack, which is hoping for
similar outputs from its protein arrays
(see Science vol. 289, p. 1673).
A star recruit
Rosetta’s primary focus is on
bioinformatics. It is a coup, then, that
they managed to hire Boguski, one of
the founding members of the US
National Center for Biotechnology
Information (NCBI). For 12 years the
NCBI has managed and massaged the
increasing £ood of public-domain
DNA sequence data.
At ¢rst, says Boguski, users of
NCBI databases had it easy. ‘‘In the
early days every [sequence database]
entry was the result of two years of
careful work. Each hit was incredibly
informative.’’ Now, he says, ‘‘you
almost always get a hit in the database
but it almost never means anything.’’
The challenge for both Boguski
and Rosetta will be to take
bioinformatics beyond its ‘my favorite
gene’ era. ‘‘Bioinformatics has not
caught up with looking at 1000 gene
queries at a time and returning
interesting and important
information,’’ he says. That sentiment
is shared by academics trying to do
their own array experiments. David
Eide (University of Missouri,
Columbia, MO) took a few days to
generate array data then ‘‘spent
several months staring at it and trying
to make sense of it,’’ he says. ‘‘The
sheer mass of data can be almost
paralyzing.’’
Big biology
Rosetta’s approach is, at its most basic,
an argument for big biology.
‘‘Absolutely that trend is going to
happen,’’ says Friend. ‘‘Once you
have a critical mass of data you can say
a lot more about the biology. But
unlike physics, a single lab can focus
in on a very narrow area and still make
a contribution.’’
Rosetta, of course, plans to be more
ambitious. Most of its test case
experiments have been in yeast, but
the company has been busy working
with mammalian cells. The results of
that work will be along shortly. ‘‘Stay
tuned,’’ says Boguski, ‘‘for some
landmark scienti¢c publications in
mammalian biology.’’
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